Form 4: Zentalis Pharmaceuticals Director Receives Stock Units

Zentalis Pharmaceuticals, Inc. reports that Director Scott Myers received 57,100 restricted stock units under the company's Non-Employee Director Compensation Program.

Summary

• Scott Myers, a Director at Zentalis Pharmaceuticals, Inc., was granted 57,100 restricted stock units (RSUs) on June 16, 2026.
• These RSUs are part of the company's Non-Employee Director Compensation Program.
• Each RSU represents a contingent right to receive one share of common stock.
• The RSUs are scheduled to vest on the earlier of June 16, 2027, or the next annual meeting of the Issuer's stockholders, provided Mr. Myers continues to serve on the Board of Directors.
• The acquisition of these securities was valued at $0, indicating they were granted as compensation rather than purchased.
• Following this transaction, Mr. Myers beneficially owns 395,895 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it reports a standard compensation transaction for a director and does not contain new financial information or strategic updates that would significantly impact the company's valuation.

Positives

• Director compensation aligns with long-term service and continued board participation through the RSU vesting schedule.
• The grant of RSUs indicates continued commitment and incentive for key leadership within the company.
• The reporting person's beneficial ownership of 395,895 shares suggests a significant stake in the company's success.

Negatives

• The RSUs were acquired at a price of $0, which is typical for grants but does not represent a new investment by the director.
• The vesting is contingent on continued service, meaning the shares are not immediately available to the director.

Risks

• The vesting of RSUs is contingent upon the reporting person's continued service on the Issuer's Board of Directors, implying a risk of forfeiture if service is terminated before the vesting date.
• The value of the RSUs is subject to the future performance and stock price of Zentalis Pharmaceuticals, Inc.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's financial performance. It solely reports a transaction related to director compensation.

Industry Context

StockSavvy.ai notes that the issuance of restricted stock units to directors is a common practice in the biopharmaceutical industry to align executive incentives with shareholder value and encourage long-term commitment. This type of compensation is standard for attracting and retaining experienced board members in a highly competitive and research-intensive sector.

Related Party Transactions

• Grant of 57,100 restricted stock units to Director Scott Myers under the Issuer's Non-Employee Director Compensation Program.

Stakeholder Impact

• Shareholders: The grant of RSUs to directors is a standard compensation practice and does not immediately dilute share value. It aligns director interests with long-term company performance.
• Employees: This filing does not directly impact employees, but it reflects the company's compensation structure for its board.
• Management: Reinforces the compensation framework for non-employee directors.

Next Steps

• Vesting of 57,100 restricted stock units on June 16, 2027, or the next annual meeting, subject to continued service.
• Continued service by Scott Myers as a Director on the Zentalis Pharmaceuticals, Inc. Board of Directors.

Key Dates

Keywords

Zentalis Pharmaceuticals, Form 4, SEC Filing, Director Compensation, Restricted Stock Units, RSU Grant, Beneficial Ownership, Stock Vesting, Scott Myers, ZNTL